Latest News on JANX

Financial News Based On Company


Advertisement
Advertisement

A passive Janux Therapeutics (JANX) holder reports shared voting power over 3.14M shares.

https://www.stocktitan.net/sec-filings/JANX/schedule-13g-a-janux-therapeutics-inc-amended-passive-investment-disc-b08b1306b0f9.html
W. Lawrence Hawkins and Prosight entities have filed an amended Schedule 13G regarding their beneficial ownership in Janux Therapeutics (JANX). Hawkins reported owning 3,150,450 shares, representing 5.15% of the company, with 3,144,200 of these shares having shared voting and dispositive power. The filing details the breakdown of ownership among Prosight entities, with percentages based on 61,183,417 JANX shares outstanding as of November 3, 2026.

Wolfe Research downgrades Janux Therapeutics to Peer Perform from Outperform

https://www.tradingview.com/news/tradingview:f9dd50d58f21e:0-wolfe-research-downgrades-janux-therapeutics-to-peer-perform-from-outperform/
Wolfe Research has downgraded Janux Therapeutics (JANX) from Outperform to Peer Perform. This action follows other recent analyst ratings, with price targets ranging from $15 to $40 over the last 30 days from firms like Truist Securities, Wedbush, and Barclays.

Janux Therapeutics downgraded by Wolfe Research

https://www.quantisnow.com/insight/janux-therapeutics-downgraded-by-wolfe-research-6786295
Wolfe Research has downgraded Janux Therapeutics (NASDAQ: JANX) to Peer Perform from Outperform, indicating reduced near-term upside potential for the stock. This downgrade follows a period where JANX experienced significant volatility after earlier headlines, including a notable drop after announcing positive initial Phase 1 data. The article also provides historical context for how JANX has traded after previous news.

H.C. Wainwright reiterates Janux Therapeutics stock rating at buy

https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-janux-therapeutics-stock-rating-at-buy-93CH-5021267
H.C. Wainwright has reiterated its Buy rating and a $45.00 price target for Janux Therapeutics (NASDAQ:JANX). Despite a recent 23% decline in the stock, analyst consensus remains at Strong Buy, with InvestingPro analysis indicating the stock is undervalued. The firm's positive stance is supported by promising Phase 1 study data for JANX011, showing dose-dependent B-cell depletion and favorable safety results.

(JANX) Movement Within Algorithmic Entry Frameworks

https://news.stocktradersdaily.com/news_release/134/JANX_Movement_Within_Algorithmic_Entry_Frameworks_111226033401_1794472441.html
This report from Stock Traders Daily provides an algorithmic analysis of Janux Therapeutics Inc. (NASDAQ: JANX), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It details three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also identifies a significant 124.7:1 risk-reward setup targeting a 31.3% gain against 0.3% risk, along with multi-timeframe signal analysis and AI-generated support and resistance levels.
Advertisement

JANX: JANX011 showed deep, sustained B-cell depletion with Grade 1-only CRS; ITP and RA studies are planned for 2027

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:4538597:0-janx-janx011-showed-deep-sustained-b-cell-depletion-with-grade-1-only-crs-itp-and-ra-studies-are-planned-for-2027/
JANX011 demonstrated deep and sustained B-cell depletion in healthy volunteers, with all observed Cytokine Release Syndrome (CRS) events being Grade 1. In 25 participants, 3 out of 5 at the 3 mg dose achieved over 90% B-cell depletion, which lasted until Day 42. Based on these positive results, Janux Therapeutics plans to initiate patient studies for Idiopathic Thrombocytopenic Purpura (ITP) in the first half of 2027 and for Rheumatoid Arthritis (RA) in the second half of 2027.

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

https://www.quantisnow.com/insight/janux-therapeutics-announces-positive-initial-phase-1-data-for-janx011-6780508
Janux Therapeutics reported positive initial Phase 1 data for JANX011 in 25 healthy volunteers, demonstrating over 90% B-cell depletion at a 3 mg dose with an acceptable safety profile. The company plans to initiate patient studies for autoimmune diseases like immune thrombocytopenia and rheumatoid arthritis in 2027. These early human data support the further development of JANX011 for autoimmune conditions.

Janux Therapeutics, Inc. (JANX) Tops Q3 EPS by 13c

https://www.streetinsider.com/Earnings/Janux+Therapeutics%2C+Inc.+%28JANX%29+Tops+Q3+EPS+by+13c/27302013.html
Janux Therapeutics, Inc. (NASDAQ: JANX) announced its Q3 earnings, reporting an EPS of ($0.34), which surpassed analyst estimates by $0.13. The company also exceeded revenue expectations, bringing in $9.29 million against a consensus estimate of $7.53 million.

Revenue fell to $9.3M at Janux Therapeutics (JANX), but its quarterly loss narrowed.

https://www.stocktitan.net/sec-filings/JANX/10-q-janux-therapeutics-inc-quarterly-earnings-report-00d91327ee59.html
Janux Therapeutics reported Q3 2026 collaboration revenue of $9.3 million and a net loss of $21.6 million, compared to $10.0 million in revenue and a $24.3 million net loss in 2025. For the nine months ended September 30, 2026, collaboration revenue increased to $23.3 million from $10.0 million in 2025, while the net loss narrowed to $67.9 million from $81.7 million. The company expects existing resources to fund operations for at least the next 12 months but anticipates substantial losses and the need for additional financing.

Form 10-Q Janux Therapeutics, Inc. For: Sep 30

https://www.streetinsider.com/SEC+Filings/Form+10-Q+Janux+Therapeutics%2C+Inc.+For%3A+Sep+30/27300640.html
Janux Therapeutics, Inc. has filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $67.9 million for the nine months ended September 30, 2026, compared to $81.7 million for the same period in 2025. The company's collaboration revenue increased due to a new agreement with Bristol-Myers Squibb Company (BMS), offsetting a decrease from the Merck Agreement. Janux also detailed its liquidity, capital resources, and risks related to its early-stage product development, reliance on third-party manufacturers, and regulatory challenges.
Advertisement

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

https://finance.yahoo.com/healthcare/articles/janux-therapeutics-inc-janx-reports-211002371.html
Janux Therapeutics, Inc. (JANX) reported a Q3 loss of $0.34 per share, surpassing the Zacks Consensus Estimate of a $0.45 loss and outperforming the previous year's loss of $0.39. The company also beat revenue estimates, posting $9.29 million against an expected $6.93 million, though this was down from $10 million a year ago. Despite a mixed outlook for estimate revisions, Janux Therapeutics currently holds a Zacks Rank #3 (Hold), indicating that its shares are expected to perform in line with the market.

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

https://finance.yahoo.com/healthcare/articles/janux-therapeutics-host-virtual-event-210200980.html
Janux Therapeutics will host a virtual event on November 9, 2026, to present initial Phase 1 clinical data for JANX011 in healthy volunteers. The presentation will cover safety, pharmacokinetics, and pharmacodynamic findings, discussing implications for JANX011's development in autoimmune diseases and the broader ARM platform. JANX011 is an investigational CD19-targeted bispecific T-cell engager from Janux's Adaptive Immune Response Modulator (ARM) platform, designed to selectively engage a defined subset of T cells.

Price-Driven Insight from (JANX) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/149/Price-Driven_Insight_from_JANX_for_Rule-Based_Strategy_110226033601_1793608561.html
This article provides a price-driven insight for Janux Therapeutics Inc. (NASDAQ: JANX), highlighting a mid-channel oscillation pattern and a positive near-term sentiment that may begin to shift. It outlines three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes a multi-timeframe signal analysis, indicating strong near-term support and resistance levels.

Janux Therapeutics, Inc. (JANX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/JANX/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Janux Therapeutics, Inc. (JANX). The chart displays the average monthly price return for the company's stock between 2021 and 2026. As of the article's timestamp, JANX stock was trading at $17.65, up 1.03%.

Janux Therapeutics stock may move 6.3% on earnings release

https://www.investing.com/news/stock-market-news/janux-therapeutics-stock-may-move-63-on-earnings-release-93CH-4988124
Janux Therapeutics Inc. (NASDAQ: JANX) stock could see a 6.3% movement following its upcoming earnings report on November 6, according to options data. Historically, the stock's actual price changes have sometimes exceeded or fallen short of implied moves from options traders in prior earnings announcements. The company has not yet confirmed the precise timing of its earnings release.
Advertisement

JANUX THERAPEUTICS, INC. : GUGGENHEIM ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $55

https://www.moomoo.com/news/flash/1002937130/janux-therapeutics-inc-guggenheim-assumes-coverage-with-buy-rating-target
Guggenheim has initiated coverage on JANUX Therapeutics, Inc. (JANX) with a Buy rating. The firm has set a price target of $55 for the company's stock, signaling a positive outlook on its future performance.

Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales

https://ca.finance.yahoo.com/news/janux-therapeutics-janx-stock-looks-082441948.html
Janux Therapeutics' stock, trading at US$18.05, appears overvalued when assessed by its sales, with a P/S ratio of 46.0x, significantly higher than the biotech industry average of 11.9x and its peer group's 3.1x. Despite a 181.2% return over the past three years, the company is still in a development-heavy stage, meaning its current valuation relies heavily on future revenue potential and clinical progress. Investors are prompted to consider if the company's pipeline and revenue outlook justify such a high premium.

Janux Therapeutics, Inc. Estimates – NASDAQ:JANX

https://www.tradingview.com/symbols/NASDAQ-JANX/financials-estimates/?category=cash_flow
This article provides an overview of Janux Therapeutics, Inc. (NASDAQ: JANX) financial estimates and actuals available on TradingView. It highlights where users can explore reported financial data, analyst estimates across various statements, and visualize trends over time. The content primarily serves as a guide for investors looking to conduct their own research on the company's financial performance.

Trading Systems Reacting to (JANX) Volatility

https://news.stocktradersdaily.com/news_release/134/Trading_Systems_Reacting_to_JANX_Volatility_102326031802_1792739882.html
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) volatility using proprietary AI models from Stock Traders Daily. It identifies a mid-channel oscillation pattern and presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The analysis highlights neutral sentiment in shorter horizons, potentially signaling an easing of a long-term weak bias, and offers specific entry, target, and stop-loss zones.

H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45

https://www.moomoo.com/news/post/1001576895/hc-wainwright-maintains-janux-therapeutics-janxus-with-buy-rating-maintains
H.C. Wainwright has reaffirmed its Buy rating on Janux Therapeutics (JANX.US) and maintained its target price at $45. This indicates a continued positive outlook from the firm regarding Janux Therapeutics' stock performance and future prospects.
Advertisement

H.C. Wainwright reiterates Janux stock rating, $45 target

https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-janux-stock-rating-45-target-93CH-4957468
H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for Janux Therapeutics (NASDAQ:JANX). The firm's analysis, supported by InvestingPro, suggests Janux is undervalued despite recent stock volatility. The company is developing several T-cell engager and immune modulator candidates, with initial healthy-volunteer data for JANX011 expected in H2 2026.

Truist Financial Maintains Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26

https://www.moomoo.com/news/post/1001316613/truist-financial-maintains-janux-therapeutics-janxus-with-buy-rating-announces
Truist Financial has reiterated its Buy rating for Janux Therapeutics (JANX.US) and set a target price of $26. This indicates a positive outlook from the firm regarding the company's stock performance.

Why (JANX) Price Action Is Critical for Tactical Trading

https://news.stocktradersdaily.com/news_release/14/Why_JANX_Price_Action_Is_Critical_for_Tactical_Trading_101226061802_1791843482.html
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) using AI models to provide tactical trading strategies. Key findings indicate strong near- and mid-term sentiment but a weak long-term outlook, with a significant risk-reward short setup identified. The analysis offers specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies across different time horizons.

Is First Patient Dosed Altering The Investment Case For Janux Therapeutics (JANX)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/news/is-first-patient-dosed-altering-the-investment-case-for-janu
Janux Therapeutics has dosed its first patient in a Phase 1 study combining JANX013 and JANX007 for metastatic castration-resistant prostate cancer, marking a key step for its precision oncology platform. This clinical trial broadens the company's prostate cancer franchise and is an execution test for its high-risk, high-spend R&D strategy, influencing its investment narrative which currently shows projected revenue growth alongside declining forecast earnings. Investors are watching trial progress, partnership milestones, and cash management for this clinical-stage biotech.

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

https://www.biospace.com/press-releases/janux-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-janx013
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013. This novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific is designed to enhance anti-tumor immune responses, particularly when combined with Janux's existing PSMA-targeted T cell engager candidates like JANX007, for patients with metastatic castration-resistant prostate cancer (mCRPC). The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013, with the goal of improving long-term outcomes for prostate cancer patients through tumor-restricted CD28 co-stimulation.
Advertisement

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

https://au.finance.yahoo.com/news/janux-therapeutics-announces-first-patient-120000097.html
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013, a novel PSMA-targeted, tumor-activated CD28 co-stimulatory bispecific. This therapy aims to enhance anti-tumor immune responses, particularly in combination with Janux's T-cell engager candidates like JANX007, for patients with metastatic castration-resistant prostate cancer (mCRPC). The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013.

Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate

https://www.marketscreener.com/news/janux-therapeutics-doses-first-participant-in-phase-1-study-of-prostate-cancer-candidate-ce785bdcdc8df42c
Janux Therapeutics has dosed the first participant in its Phase 1 study for a prostate cancer candidate. The company, a clinical-stage biopharmaceutical firm, is developing tumor-activated immunotherapies and has multiple bispecific platforms. This new study highlights their ongoing efforts in targeting various cancers with innovative treatments.

Price-Driven Insight from (JANX) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/15/Price-Driven_Insight_from_JANX_for_Rule-Based_Strategy_091126072802_1789169282.html
This article provides a price-driven analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating a near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It highlights a mid-channel oscillation pattern and an exceptional short setup with a 107.6:1 risk-reward ratio. The analysis presents institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels.

Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23

https://www.moomoo.com/news/post/75149141/wolfe-research-initiates-janux-therapeutics-janxus-with-buy-rating-announces
Wolfe Research has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a price target of $23 for the company's shares. This initiation suggests a positive outlook from Wolfe Research regarding Janux Therapeutics' future performance.

Wolfe Research upgrades Janux stock rating on autoimmune data

https://m.investing.com/news/analyst-ratings/wolfe-research-upgrades-janux-stock-rating-on-autoimmune-data-93CH-4872954?ampMode=1
Wolfe Research upgraded Janux Therapeutics shares from Peerperform to Outperform with a $23 price target, citing upcoming autoimmune data as a key catalyst. The stock has shown volatility and is considered undervalued by InvestingPro. Janux also recently announced the departure of its Chief Medical Officer, William Go, and is actively seeking a replacement.
Advertisement

Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?

https://www.sahmcapital.com/news/content/is-janux-therapeutics-janx-narrowing-losses-enough-to-shift-its-long-term-risk-profile-2026-08-20
Janux Therapeutics (JANX) reported reduced net losses and lower basic loss per share for Q2 and the first six months of 2026, indicating more efficient cost management. While this eases near-term financing concerns for the pre-profit biotech, its investment narrative still hinges on the success of its TRACTr and ARM platforms, clinical trial data, and the Bristol Myers Squibb partnership. The company faces significant risks related to trial outcomes, cash burn, potential dilution, and a potentially inflated share price compared to its estimated value.

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

https://www.tradingview.com/news/zacks:2f2b8e02a094b:0-janx-shares-gain-19-1-in-3-months-here-s-what-you-need-to-know/
Janux Therapeutics (JANX) shares have increased by 19.1% over the past three months and 25.3% year-to-date, driven by advancements in its oncology and autoimmune pipelines. Key developments include progress in prostate cancer candidate JANX007 and the launch of autoimmune candidate JANX011. The company also maintains strategic collaborations with Merck & Co. and Bristol Myers Squibb and boasts a strong balance sheet with $970.9 million in cash.

Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/news/is-janux-therapeutics-janx-narrowing-losses-enough-to-shift/amp
Janux Therapeutics (JANX) reported reduced net losses of US$21.97 million for Q2 2026 and US$46.33 million for the six-month period, indicating more efficient cost management. While these narrowing losses ease near-term financing concerns, Janux remains a pre-profit, high-spend biotech company heavily reliant on future clinical trial outcomes and its partnership with Bristol Myers Squibb. Investors are advised to consider the company's valuation report, which suggests an inflated share price compared to its estimated value.

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

https://www.marketbeat.com/instant-alerts/janux-therapeutics-inc-nasdaqjanx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-08-20/
Janux Therapeutics (NASDAQ:JANX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $37.58, despite some recent price target reductions. The company's stock opened at $17.52 with a market capitalization of $1.07 billion, and its latest quarterly results missed analyst expectations for both EPS and revenue. Institutional investors hold a significant 75.39% stake in Janux Therapeutics, a clinical-stage biotechnology company focused on immuno-oncology therapies.

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3861011/analysts-offer-insights-on-healthcare-companies-janux-therapeutics-inc-janx-and-ginkgo-bioworks-holdings-dna/
This article provides analyst insights for two healthcare companies, Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA). William Blair analyst Matt Phipps maintained a Buy rating for Janux Therapeutics Inc, while William Blair analyst Jared Haase maintained a Sell rating for Ginkgo Bioworks Holdings. The article details analyst consensus, price targets, and recent stock performance for both companies.
Advertisement

Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX

https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-134-million-stake-in-janux-therapeutics-inc-janx-2026-08-15/
Dimensional Fund Advisors LP significantly reduced its stake in Janux Therapeutics, Inc. by 56.9% in the first quarter, now holding 96,630 shares valued at approximately $1.34 million. Despite Janux Therapeutics missing consensus estimates for its recent quarterly earnings and revenue, institutional investors collectively own 75.39% of the company's stock. Analysts currently rate JANX as a "Moderate Buy" with a consensus price target of $37.58, which is substantially higher than its recent trading price of $16.12.

Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund

https://www.stocktitan.net/sec-filings/JANX/schedule-13g-a-janux-therapeutics-inc-amended-passive-investment-disc-debb5fd4c51d.html
Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is held through investment funds managed by Point72, with shared voting and dispositive power among the reporting persons. The filing, a Schedule 13G/A, indicates that the ownership is below 5% and is for passive investment purposes.

Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management

https://www.stocktitan.net/sec-filings/JANX/schedule-13g-a-janux-therapeutics-inc-amended-passive-investment-disc-c8753a63a745.html
Janus Henderson Group Ltd. has reported beneficial ownership of 172,229 shares of Janux Therapeutics, Inc. common stock, which represents a 0.3% stake in the company. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, and the group exercises shared voting and dispositive power over them. The filing clarifies that the dividends and sale proceeds from these shares accrue to the Managed Portfolios, not Janus Henderson directly, and no single Managed Portfolio holds more than five percent of Janux Therapeutics' common stock.

Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35

https://www.moomoo.com/news/post/74600618/stifel-maintains-janux-therapeutics-janxus-with-buy-rating-maintains-target
Stifel has reiterated its Buy rating for Janux Therapeutics (JANX.US) and maintained its target price at $35. This indicates a continued positive outlook from the investment firm regarding the company's stock performance.

The Janux Therapeutics, Inc. (NASDAQ:JANX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

https://www.moomoo.com/news/post/74492420/the-janux-therapeutics-inc-nasdaq-janx-second-quarter-results-are
Janux Therapeutics reported its second-quarter results, showing significant revenue growth from collaborations and a substantial cash reserve. Analysts have updated their forecasts, maintaining a "buy" consensus with a new average price target of US$47.90, indicating a potential 30% upside from the current share price. The company's financial health appears strong, supported by its cash position and ongoing R&D investments.
Advertisement

Equities Analysts Set Expectations for JANX Q3 Earnings

https://www.marketbeat.com/instant-alerts/equities-analysts-set-expectations-for-janx-q3-earnings-2026-08-12/
HC Wainwright has revised its Q3 2026 EPS estimate for Janux Therapeutics (NASDAQ:JANX) to a loss of $0.45 per share, an improvement from its previous estimate. Despite this, Janux Therapeutics recently reported quarterly earnings that fell short of expectations, with an EPS loss of $0.35 against an estimated $0.25 loss and lower-than-expected revenue. The company maintains a "Moderate Buy" analyst rating with an average price target of $37.58, while institutional investors hold a significant 75.39% stake in the stock.

HC Wainwright Has Negative Outlook of JANX FY2030 Earnings

https://www.marketbeat.com/instant-alerts/hc-wainwright-has-negative-outlook-of-janx-fy2030-earnings-2026-08-11/
HC Wainwright has lowered its FY2030 earnings per share (EPS) estimate for Janux Therapeutics (NASDAQ:JANX) to $0.97, down from $1.06, while the consensus remains a loss of $1.70 per share. This adjustment follows Janux's recent quarterly earnings report, where the company missed analyst expectations with a loss of $0.35 per share and revenue of $10.27 million against an anticipated $19.07 million. Despite the lowered forecast and recent price target reductions from other analysts, Janux Therapeutics still holds a "Moderate Buy" consensus rating with an average target price significantly higher than its current share price.

Janux Therapeutics Inc (JANX) Stock News Today

https://www.tradingkey.com/markets/stocks/janx/news
This article provides an overview of Janux Therapeutics Inc (JANX) stock information, including its current trading price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the platform for users interested in the company.

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile

https://finance.yahoo.com/healthcare/articles/janux-therapeutics-janx-7-1-101032298.html
Janux Therapeutics (JANX) saw its stock rise by 7.1% after announcing a narrower net loss for the second quarter and first half of 2026. The company reported a net loss of US$21.97 million, or US$0.35 per share, in Q2 2026, an improvement from US$33.86 million, or US$0.55 per share, a year prior. While this indicates better cost control, the article notes that funding needs and dilution risk remain key concerns for investors due to the company's high valuation multiples and ongoing unprofitability.

RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating

https://www.moomoo.com/news/post/74420300/rbc-adjusts-price-target-on-janux-therapeutics-to-34-from
RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company.
Advertisement

Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/news/analysts-have-lowered-expectations-for-janux-therapeutics-in
Janux Therapeutics, Inc. (NASDAQ:JANX) missed its latest quarterly earnings expectations, with revenues significantly lower than forecasts and per-share losses exceeding predictions. As a result, analysts have reduced their revenue estimates for 2026 and increased their loss per share forecasts, though the consensus price target remains largely unchanged. Despite these adjustments, the company's projected revenue growth is still expected to be in line with the broader industry.

RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating

https://www.marketscreener.com/news/rbc-adjusts-price-target-on-janux-therapeutics-to-34-from-30-maintains-outperform-rating-ce7f50d3d08df522
RBC Capital has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating. This adjustment comes after Janux Therapeutics reported its Q2 revenue of $10.3 million, falling short of FactSet's estimate of $19.1 million. The company is a clinical-stage biopharmaceutical firm focusing on tumor-activated immunotherapies for cancer.

Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results

https://www.sahmcapital.com/news/content/analysts-have-lowered-expectations-for-janux-therapeutics-inc-nasdaqjanx-after-its-latest-results-2026-08-10
Analysts have reduced their revenue and increased their loss per share forecasts for Janux Therapeutics (NASDAQ:JANX) after the company missed earnings in its latest quarterly results. Despite the lowered expectations, the consensus price target remains largely unchanged, suggesting that the intrinsic value of the business is perceived to be stable. The company's revenue growth is still expected to align with the industry average, but investors are advised to focus on the long-term trajectory.

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

https://www.theglobeandmail.com/investing/markets/stocks/JANX-Q/pressreleases/3734698/bank-of-america-securities-sticks-to-its-buy-rating-for-janux-therapeutics-inc-janx/
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $22.00. While other analysts like William Blair also issued a Buy rating, Barclays maintained a Sell rating. The company recently reported a quarterly revenue of $3.73 million and a GAAP net loss of $24.36 million, and corporate insider sentiment is negative due to increased insider selling.

Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside

https://www.tradingview.com/news/tradingview:48270f6b5b567:0-janux-therapeutics-inc-stock-12-month-price-target-cut-to-33-25-implies-107-upside/
Janux Therapeutics, Inc.'s average 12-month price target has been slightly reduced by analysts from $33.56 to $33.25, with a range of $14 to $60 per share. Despite the cut, the new target still implies a significant 107% potential upside based on the Aug. 6 closing price. The consensus rating for the stock remains a "Buy" among 18 covering analysts.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement